Skip to content
Buy This GLP
← Research
Evidence

Can You Buy Retatrutide? FDA Status and Clinical Trial Results

Retatrutide remains investigational, and FDA says it cannot be used in compounding. See what the peer-reviewed phase 2 and phase 3 trials found.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
Phase 2 weight loss at 24 and 48 weeksplacebo2.1%1 mg8.7%4 mg17.1%8 mg22.8%12 mg24.2%338 adults. Light bars show week 24 within week 48.

As of November 14, 2026, retatrutide has no FDA-approved product in the United States. The FDA says it cannot be used in compounding under federal law and has warned companies about marketing it directly to consumers.[3] The guide to compounded GLP-1 sourcing explains which pharmacy details can be verified for other medications. A pharmacy name on an advertised retatrutide vial does not establish its contents or safety.

What the peer-reviewed phase 3 trial found

TRIUMPH-1 randomly assigned 2,339 adults with obesity and without diabetes to retatrutide or placebo for 80 weeks. In the trial’s main weight analysis, the estimated mean weight losses were 17.6%, 23.7%, and 25.0% in the 4 mg, 9 mg, and 12 mg groups and 3.9% with placebo. The analysis assessed participants by assigned treatment group. Gastrointestinal side effects were the most common. Eli Lilly funded the trial.[2]

For readers comparing weight-loss estimates across treatments, the comparator, the participants’ health conditions, and follow-up time affect how to read each result. TRIUMPH-1 compared retatrutide with placebo in adults without diabetes. Separately, in October 2026 Lilly released topline results from TRANSCEND-T2D-2, an open-label comparison with injectable semaglutide 2 mg in adults with type 2 diabetes. That source is a sponsor announcement for a different study.[2][4]

What the earlier phase 2 trial adds

The phase 2 trial randomized 338 adults with obesity or overweight and a weight-related condition. At week 48, estimated average weight loss was 8.7% in the 1 mg group, 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group, compared with 2.1% with placebo.[1]

Gastrointestinal side effects were dose-related and mostly mild to moderate. Increases in heart rate also varied by dose, peaked at 24 weeks, and declined afterward. The trial was funded by Eli Lilly.[1]

What the trial results mean for products advertised online

These results describe the drug supplied and monitored in clinical trials. They cannot verify the identity, strength, or safety of a vial advertised online. FDA warns consumers against purchasing products sold for human use under labels such as “for research purposes.”[3]

Frequently asked

Can you buy retatrutide?
There is no FDA-approved retatrutide product. FDA says retatrutide cannot be used in compounding and has warned about products marketed directly to consumers.
How much weight did people lose in the trials?
In phase 3 TRIUMPH-1, estimated average weight loss at 80 weeks was 25.0% with 12 mg and 3.9% with placebo. The earlier phase 2 trial estimated 24.2% and 2.1% at 48 weeks for the same target dose and placebo. The trials had different participants and follow-up.
Were there safety findings?
In phase 2, heart rate rose in a dose-dependent way, peaked at 24 weeks, and declined afterward. Gastrointestinal effects were common in both trials.

Sources

  1. [1] Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial New England Journal of Medicine. PMID 37366315
  2. [2] Jastreboff AM, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity New England Journal of Medicine. PMID 42814954
  3. [3] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source
  4. [4] Eli Lilly and Company (2026). TRANSCEND-T2D-2 phase 3 topline results, October 28, 2026 Eli Lilly and Company. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence